A review published earlier this month linked the mRNA in COVID-19 vaccines to the development of cancer.
mRNA’s N1-methyl-pseudouridine modification is believed to cause immune suppression that leads to cancer concerns.
“Evidence is provided that adding 100% of N1-methyl-pseudouridine (m1Ψ) to the mRNA vaccine in a melanoma model stimulated cancer growth and metastasis, while non-modified mRNA vaccines induced opposite results, thus suggesting that COVID-19 mRNA vaccines could aid cancer development,” the authors wrote.
“[W]e suggest that future clinical trials for cancers or infectious diseases should not use mRNA vaccines with a 100 % m1Ψ modification, but rather ones with the lower percentage of m1Ψ modification to avoid immune suppression,” they added.
A recent Japanese study published in the journal Cureus also linked COVID-19 vaccines to excess cancer deaths.
“[S]ome excess cancer mortalities were observed in 2021 after mass vaccination with the first and second vaccine doses, and significant excess mortalities were observed for all cancers and some specific types of cancer (including ovarian cancer, leukemia, prostate cancer, lip/oral/pharyngeal cancer, pancreatic cancer, and breast cancer) after mass vaccination with the third dose in 2022,” the researchers stated.
In 2020, there were no excess deaths for all cancers. Beginning in 2021, however, there was a “significant excess mortality of 2.1% for all causes and 1.1% for all cancers.”
The trend of excess mortality continued throughout 2022, with a 9.6% increase in excess deaths for all causes and a 2.1% increase for all cancers.
Retired English nurse John Campbell released a video discussing the Japanese study, in which he said, “The Japanese researchers are strongly suspecting and give good evidence for increased instance of several types of cancer, especially after the third booster dose of vaccine.”
Campbell noted that the data does not represent new cancer cases, only deaths from cancer.
Despite the health risks presented in mRNA vaccines, Moderna announced that it is developing more mRNA vaccines targeting Epstein-Barr virus (EBV), Varicella-zoster virus (VZV), and Norovirus.
Stéphane Bancel, Chief Executive Officer of Moderna, stated that Moderna’s goal is to “launch multiple vaccine products in the next few years and deliver the greatest possible impact to people through mRNA medicines.”